Inductos
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Dibotermin alfa
- Used in
- Muscles, joints and bones
- Made by
- Medtronic BioPharma B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition. Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Medtronic BioPharma B.V. |
|---|---|
| Active substance | Dibotermin alfa |
| Used in | Muscles, joints and bones |
| Classification | M05BC01 · Muscles, joints and bones |
| Authorised on | 2002-09-09 |
| Last updated by the regulator | 2021-10-18 |
| EMA product number | EMEA/H/C/000408 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).